NextCell Pharma Full Year 2024 Earnings: kr1.22 loss per share (vs kr1.16 loss in FY 2023)
NextCell Pharma (STO:NXTCL) Full Year 2024 Results
Key Financial Results
- Revenue: kr11.3m (down 19% from FY 2023).
- Net loss: kr42.0m (loss widened by 5.4% from FY 2023).
- kr1.22 loss per share (further deteriorated from kr1.16 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NextCell Pharma shares are down 11% from a week ago.
Risk Analysis
It is worth noting though that we have found 5 warning signs for NextCell Pharma (2 can't be ignored!) that you need to take into consideration.
Valuation is complex, but we're here to simplify it.
Discover if NextCell Pharma might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:NXTCL
NextCell Pharma
A biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden.
Flawless balance sheet moderate.
